NEK8 and central nervous system cancer: NEK8 expression in glioma was significantly associated with the WHO grade (OR = 3.05 for Grade IV vs. II and III), IDH status (OR = 4.60 for WT vs. Mutant), EGFR status (OR = 4.07 for WT vs. Mutant), PIK3CA status (OR = 2.17 for WT vs. Mutant), primary therapy outcome (OR = 0.58 for CR vs. PD, SD and PR), age (OR = 0.31 for ≤60 years vs. >60 years), and histological type (OR = 2.91 for astrocytoma vs. glioblastoma).